#USA #New York #Class Action #Faruqi & Faruqi #Soleno Therapeutics

Investors Alert: Deadline Approaching for Soleno Therapeutics Class Action

Faruqi & Faruqi, a notable name in the field of securities law, has issued an urgent reminder to investors regarding Soleno Therapeutics, Inc. As the deadline of May 5, 2026, for filing lead plaintiff motions in a federal securities class action draws near, stakeholders are encouraged to explore their legal options.

Background of the Case

In 2025, accusations surfaced against Soleno Therapeutics related to its Phase 3 clinical trials for DCCR, a treatment for hyperphagia in Prader-Willi syndrome (PWS). Allegations detailed that the company not only misrepresented the safety concerns linked to the drug but also failed to adequately disclose the significant risks involved. These issues became public following a critical report from Scorpion Capital, resulting in a notable decline in the stock's value and raising alarms among investors.

Faruqi & Faruqi, led by prominent partner James (Josh) Wilson, is spearheading the investigation into these claims, emphasizing the importance of getting in touch if any investors suffered losses during the specified period between March 26, 2025, and November 4, 2025. Wilson notes that potential participants in the class action are strongly encouraged to reach out to discuss their legal rights.

Implications for Soleno Investors

The repercussions of the information disclosed in the Scorpion report and subsequent admissions by Soleno have caused substantial fluctuations in stock prices. Notably, after a patient died post-DCCR treatment, shares plummeted significantly, highlighting the serious nature of the allegations. Soleno's financial documentation post these events also indicated a concerning decline in the uptake of the drug, signaling potential long-term risks to both patients and investors.

What Investors Should Do

Investors are advised to act quickly. Participating in the class action does not require being the lead plaintiff, yet any individual with information related to Soleno's operations is encouraged to come forward. This includes whistleblowers and previous employees who might provide critical insights. For those wishing to be involved, contact details for Faruqi & Faruqi are readily available, where further guidance can be offered.

Conclusion

As the May 5 deadline approaches, investors in Soleno Therapeutics should closely monitor their options. The potential for claiming losses linked to the company's alleged misconduct exists but requires prompt action. Faruqi & Faruqi is prepared to guide affected stakeholders through the legal process, emphasizing that previous experiences have led to successful recoveries for clients in similar situations. Interested parties can learn more and find resources at the firm’s official website or reach out directly to Wilson for immediate assistance.